H3 Biomedicine
E387619
H3 Biomedicine is a biotechnology company focused on discovering and developing precision cancer therapies using genomics-driven approaches.
All labels observed (1)
| Label | Occurrences |
|---|---|
| H3 Biomedicine canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T3803133 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: H3 Biomedicine Context triple: [Stuart L. Schreiber, coFounderOf, H3 Biomedicine]
-
A.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
B.
Samsung Biologics
Samsung Biologics is a South Korean biopharmaceutical company specializing in contract development and manufacturing (CDMO) of biologic drugs for global pharmaceutical and biotech firms.
-
C.
Verily Life Sciences LLC
Verily Life Sciences LLC is a health-focused research and technology company that develops tools and platforms to collect, organize, and analyze health data, particularly in areas like clinical research, precision health, and disease management.
-
D.
ICMBio
ICMBio is Brazil’s federal agency responsible for managing and protecting the country’s conservation units and biodiversity.
-
E.
BioNTech
BioNTech is a German biotechnology company best known for developing one of the first mRNA-based COVID-19 vaccines in partnership with Pfizer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: H3 Biomedicine Target entity description: H3 Biomedicine is a biotechnology company focused on discovering and developing precision cancer therapies using genomics-driven approaches.
-
A.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
B.
Samsung Biologics
Samsung Biologics is a South Korean biopharmaceutical company specializing in contract development and manufacturing (CDMO) of biologic drugs for global pharmaceutical and biotech firms.
-
C.
Verily Life Sciences LLC
Verily Life Sciences LLC is a health-focused research and technology company that develops tools and platforms to collect, organize, and analyze health data, particularly in areas like clinical research, precision health, and disease management.
-
D.
ICMBio
ICMBio is Brazil’s federal agency responsible for managing and protecting the country’s conservation units and biodiversity.
-
E.
BioNTech
BioNTech is a German biotechnology company best known for developing one of the first mRNA-based COVID-19 vaccines in partnership with Pfizer.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
biotechnology company
ⓘ
cancer drug development company ⓘ |
| aimsTo |
develop more effective and less toxic cancer treatments
ⓘ
match therapies to specific genetic alterations in cancer ⓘ |
| approach |
data-driven drug discovery
ⓘ
patient stratification using genomics ⓘ |
| businessModel | research and development of oncology drugs ⓘ |
| collaboratesWith |
academic research institutions
ⓘ
clinical research centers ⓘ |
| conducts |
clinical development of oncology drugs
ⓘ
preclinical cancer research ⓘ |
| develops |
genomics-guided therapeutics
ⓘ
precision oncology drugs ⓘ small-molecule cancer therapies ⓘ |
| field |
biomedicine
ⓘ
translational oncology ⓘ |
| focusesOn |
biomarker-driven clinical trials
ⓘ
identification of predictive biomarkers ⓘ oncology ⓘ precision cancer therapies ⓘ |
| goal |
develop targeted treatments for specific cancer subtypes
ⓘ
improve outcomes for cancer patients ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| mission | advance precision medicine in oncology ⓘ |
| productType | investigational cancer therapies ⓘ |
| researchArea |
cancer genomics
ⓘ
molecular oncology ⓘ targeted therapies ⓘ |
| specializesIn |
genomic profiling of tumors
ⓘ
oncology therapeutics ⓘ targeted cancer therapies ⓘ |
| strategy |
identification of genomic drivers of cancer
ⓘ
precision oncology based on tumor genomics ⓘ |
| targetCustomer |
healthcare providers treating cancer
ⓘ
oncology patients ⓘ |
| therapeuticArea |
hematologic malignancies
ⓘ
solid tumors ⓘ |
| usesApproach |
genomics-driven drug discovery
ⓘ
patient selection based on genomic biomarkers ⓘ precision medicine ⓘ |
| usesData |
patient genomic data
ⓘ
tumor mutation profiles ⓘ |
| usesTechnology |
bioinformatics
ⓘ
computational biology ⓘ genomic sequencing ⓘ molecular profiling ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: H3 Biomedicine Description of subject: H3 Biomedicine is a biotechnology company focused on discovering and developing precision cancer therapies using genomics-driven approaches.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.